Zobrazeno 1 - 10 of 246 pro vyhledávání: '"E. Drescher"'
1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
3
A Comparative Study to Assess the Efficacy, Safety, and Immunogenicity of YLB113 and the Etanercept Reference Product for the Treatment of Patients with Rheumatoid Arthritis
Autor: Toshihiko Hibino, Juan Sánchez-Bursón, E. Drescher, Naoyuki Kamatani, Chirag Shah, Yoshiya Tanaka, Dhananjay Bakhle, Hisashi Yamanaka, Manfred Rettenbacher, Girish Bhatia, Snehal Ameet Gadve
Publikováno v: Rheumatology and Therapy
Rheumatology and Therapy, Vol 7, Iss 1, Pp 149-163 (2019)
Introduction YLB113 is a biosimilar of the reference product (RP), etanercept, under development for treatment of patients with moderate-to-severe rheumatoid arthritis (RA) and other approved indications. A phase 3 study was conducted in Europe, Japa
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::144d39f4ca6c70fbc856e0c3461171e9
http://europepmc.org/articles/PMC7021908
Zobrazit plný text záznamu
4
OP0258 IZOKIBEP (ABY-035) IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS – 16-WEEK RESULTS FROM A PHASE 2 STUDY
Autor: F. Behrens, P. C. Taylor, D. Wetzel, N. C. Brun, J. Brandt-Juergens, E. Drescher, E. Dokoupilova, A. Rowińska-Osuch, N. Abdel-Kader Martin, K. de Vlam
Publikováno v: Annals of the Rheumatic Diseases. 81:170-171
BackgroundPsoriatic arthritis (PsA) is a chronic, immune-mediated inflammatory disease with heterogenous musculoskeletal manifestation (arthritis, spondylitis, enthesitis, dactylitis) and extra-musculoskeletal manifestation (skin and nail psoriasis).
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8e229dbbcf5a28957ab57382077cf316
https://doi.org/10.1136/annrheumdis-2022-eular.536
Zobrazit plný text záznamu
6
POS1030 EFFICACY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS STRATIFIED BY BASELINE SKIN SEVERITY: A SUBGROUP ANALYSIS OF TWO PHASE III TRIALS
Autor: Mitsumasa Kishimoto, E. Drescher, Joseph F. Merola, M. Lane, Lilian Soto, R. Lippe, C. Lovan, Pascal Richette, Ennio Lubrano, K. Kato
Publikováno v: Annals of the Rheumatic Diseases. 80:786-787
Background:In the SELECT-PsA 1 and 2 clinical trials, upadacitinib (UPA) demonstrated efficacy and safety in patients (pts) with active psoriatic arthritis (PsA).1,2 PsA is associated with varying degrees of psoriatic symptoms; however, the impact of
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c9c73a6abd4d0fd05dcac2beeaa4027c
https://doi.org/10.1136/annrheumdis-2021-eular.536
Zobrazit plný text záznamu
7
AB0416 A COMPARATIVE STUDY TO ASSESS THE EFFICACY, SAFETY, AND IMMUNOGENICITY OF YLB113 AND ETANERCEPT REFERENCE PRODUCT FOR THE TREATMENT OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS
Autor: Juan Sánchez-Bursón, E. Drescher, Yoshiya Tanaka, Naoyuki Kamatani, Hisashi Yamanaka, Girish Bhatia, Chirag Shah, Toshihiko Hibino, Dhananjay Bakhle, Manfred Rettenbacher, Snehal Ameet Gadve
Publikováno v: Abstracts Accepted for Publication.
Background YLB113 is an investigational biosimilar of the reference product etanercept (ETN), being developed for the treatment of patients with moderate-to-severe rheumatoid arthritis (RA) and other approved indications of the reference product ETN.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a0320ee88233248dfc2bd1a45bb80d64
https://doi.org/10.1136/annrheumdis-2019-eular.2844
Zobrazit plný text záznamu
8
POS0508 EVALUATION OF RESPONSE TO PNEUMOCOCCAL VACCINATION IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING UPADACITINIB: RESULTS FROM A PHASE 2 OPEN-LABEL EXTENSION STUDY
Autor: Kevin L. Winthrop, J. Ignacio Vargas, Alan Friedman, Alan Kivitz, J. Enejosa, N. Khan, C. Garcia Garcia, E. Drescher, J. Klaff, Y. Li
Publikováno v: Annals of the Rheumatic Diseases. 80:486.3-487
Background:Pneumococcal vaccination is recommended in patients with RA who are receiving conventional synthetic/biologic DMARDs.1 Upadacitinib (UPA) is an oral Janus kinase (JAK) inhibitor engineered to have a greater selectivity for JAK1 versus JAK2
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5e49bd9e3759e8c4e66338b30855c773
https://doi.org/10.1136/annrheumdis-2021-eular.559
Zobrazit plný text záznamu
9
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
Autor: Douglas E Schlichting, Terence Rooney, Paul Emery, Désirée van der Heijde, Ying-Chou Chen, Inmaculada de la Torre, Maria Greenwald, E. Drescher, Scott D. Beattie, Maxime Dougados, Sarah Witt, Jiajun Liu, Carol L. Gaich, Stephanie de Bono
Publikováno v: Annals of the Rheumatic Diseases, 76(1), 88-95
Annals of the Rheumatic Diseases
BackgroundBaricitinib is an oral, reversible, selective Janus kinase 1 and 2 inhibitor.MethodsIn this phase III, double-blind 24-week study, 684 biologic disease-modifying antirheumatic drug (DMARD)-naïve patients with rheumatoid arthritis and inade
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c1a7ced5306198ac4947c3175dd1eb8
https://doi.org/10.1136/annrheumdis-2016-210094
Zobrazit plný text záznamu
10
Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
Autor: William L. Macias, Mark C. Genovese, Rosanne Fidelus-Gort, E. Drescher, Terence Rooney, Douglas E Schlichting, Scott D. Beattie, Chin Lee, Edward C. Keystone, Peter C. Taylor, Pierre-Yves Berclaz, Monica E. Luchi
Publikováno v: Annals of the Rheumatic Diseases
OBJECTIVES: To investigate baricitinib (LY3009104, formerly INCB028050), a novel, oral inhibitor of JAK1/JAK2 in patients with moderate to severe rheumatoid arthritis (RA) despite treatment with methotrexate. METHODS: In this phase IIb study, 301 pat
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96188933c55c059b8d72fbbdf0ddae02
http://europepmc.org/articles/PMC4316868
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje